MEDICINOVA, INC. (MNOV) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 2.96M USD | Liabilities, Current |
| Cash and equivalents | 25.42M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 0.00 USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $2.96M | $25.42M | (m) | $0.00 | (m) | (m) |
| 2026-03-31 | (m) | $3.10M | $27.33M | (m) | $245.10K | (m) | (m) |
| 2025-12-31 | (m) | $3.80M | $30.81M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $3.34M | $32.56M | (m) | $0.00 | (m) | (m) |
| 2025-06-30 | (m) | $2.65M | $34.26M | (m) | $134.60K | (m) | (m) |
| 2025-03-31 | (m) | $2.13M | $36.57M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $2.96M | $40.36M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $2.60M | $42.28M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $2.49M | $44.34M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $2.51M | $47.14M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $3.28M | $51.00M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $2.80M | $51.51M | (m) | $1.00M | (m) | (m) |
| 2023-06-30 | (m) | $2.82M | $52.88M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $2.72M | $55.26M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $3.19M | $18.51M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $4.53M | $52.51M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $3.84M | $65.23M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $2.98M | $67.70M | (m) | (m) | (m) | (m) |
| 2022-01-01 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) |
| 2021-12-31 | (m) | $2.83M | $71.43M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $4.20M | $75.03M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $2.47M | $77.79M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $1.83M | $76.30M | (m) | $4.00M | (m) | (m) |
| 2020-12-31 | (m) | $2.19M | $60.04M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $1.80M | $61.66M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $2.77M | $60.44M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $1.79M | $61.33M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $2.23M | $63.79M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $1.73M | $62.87M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $1.79M | $61.74M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $1.37M | $63.21M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $2.19M | $62.31M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $1.80M | $62.44M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $1.57M | $64.16M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $1.20M | $62.94M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $2.88M | $27.99M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $1.74M | $24.54M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $1.42M | $22.89M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $1.02M | $21.64M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $1.63M | $24.12M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $1.38M | $24.97M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $1.33M | $26.57M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $1.05M | $27.62M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $1.49M | $22.08M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $1.30M | $23.61M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $1.11M | $8.58M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $853.03K | $9.07M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $1.59M | $11.67M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $1.13M | $11.94M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $1.10M | $13.50M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $901.82K | $14.78M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $460.44K | $6.70M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $1.10M | $10.66M | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $1.08M | $12.02M | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $948.15K | $3.03M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $1.04M | $4.01M | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $1.16M | $5.74M | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $3.21M | $7.26M | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $2.74M | $11.01M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $3.70M | $15.09M | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | $3.43M | $8.74M | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $2.45M | $11.92M | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $31.38M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $36.79M | $28.25M | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $31.16M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $25.36M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $19.24M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $19.30M | (m) | (m) | (m) | (m) |
| 2000-12-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2000-09-25 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |